Shares of Biotechnology company InterMune Inc (NASDAQ: ITMN) are up 35% after announcing a late-stage study of its investigational treatment for a potentially fatal lung disease met the main goal, even as another late-stage trial of the same drug failed.
read more
Related Headlines
- Take-Two at $6.80 a Share (TTWO) but for How Long?posted 747 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo
- Say it Ain't So - Evergreen Solar (ESLR) at $1.80 a share?posted 746 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo
- SanDisk Tanks below $9 a Share (SNDK)posted 747 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo
- Dendreon's Q3 Conference Call happens todayposted 811 weeks ago on The StockMasters - Investing News and Analysis, Hot Stock Tips, Stock Marke
- Denny's Corp. (DENN) the Real Winner of Super Bowl 43posted 747 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo
- WPT Enterprises, Inc. (WPTE) shares are down to 35 centsposted 747 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo
- Where the 'Financial Gurus' are Investing (MO, GE, Bonds)posted 747 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo
- WallStNation.com: Bank of America to Nationalize (BAC)?posted 747 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo
- 'Bad Bank' Plans, let's Run with the Bulls (FAS)posted 748 weeks ago on The StockMasters - Financial News, Stock Market Trading, the Best Stocks fo